

RECEIVED

7007 OCT 26 P 1:41


FRI OCT 26 2007

Carl Zeiss Meditec AG 07740 Jena Germany

Securities and Exchange Commission  
 Division of Corporation Finance  
 Office of International Corporate Finance  
 450 Fifth Street, N. W.

Washington, D. C. 20549  
 United States

Division/ Dept.: Investor Relations  
 Your contact: Jens Brajer



07027560

Carl Zeiss Meditec AG  
 Goeschwitzer Strasse 51-52  
 07745 Jena  
 Germany

Tel: +49 (0) 36 41/220-105

Fax: +49 (0) 36 41/220-117

e-mail: j.brajer@meditec.zeiss.com

Our ref.: JB/Mtr

Date: 2007-10-18

File No. 82-34817

Dear Ladies and Gentlemen,

Please find attached the following document that was released to our shareholders:

Type of document	Date of release
Press Release	2007-10-16

Best regards,

Carl Zeiss Meditec AG  
 i. V.

Jens Brajer  
 Director Investor Relations

i. A.

Mandy Pfeil  
 Assistant Investor Relations

PROCESSED

OCT 30 2007  
 THOMSON  
 FINANCIAL

Board of Management:  
 Ulrich Krauss (CEO)  
 Bernd Hirsch  
 Dr. Ludwin Monz  
 James L. Taylor  
 Chairman of the Supervisory Board:  
 Dr. Michael Kaschke

Deutsche Bank AG Jena  
 Account: 62 453 69 (BLZ: 820 700 00)  
 SWIFT: DEUT DE 8E  
 IBAN: DE90820700000624536900  
 Commercial register:  
 Gera, HRB 5623  
 VAT-IdNo. DE 811 922 737  
 Tax-No. 64003/ 02707

Commerzbank Jena  
 Account: 258072800 (BLZ: 820 40000)  
 SWIFT: COBADEFFXXX  
 IBAN: DE31820400000258072800  
 Phone: +49 (0) 36 41/ 220-0  
 Fax: +49 (0) 36 41/ 220-112  
 Internet: www.meditec.zeiss.com  
 e-mail: info@meditec.zeiss.com





"Overall, our goal was to give participants a better insight into our positioning as an integrated medical technology company", said Ulrich Krauss, CEO and President of Carl Zeiss Meditec AG. "We wanted to present our individual growth drivers in the SBUs Surgical Ophthalmology, Ophthalmological Systems and Neuro/ENT Surgery in a clear and tangible way. The discussion this prompted following the presentations showed us that this mission was successfully accomplished."

**Press Release**



### **Brief profile**

Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation.

The company has two primary areas of activity: In the field of **ophthalmology** Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. The company's system solutions are employed in all phases of the disease management, from diagnosis to treatment and follow-up. Carl Zeiss Meditec has always applied its technological expertise to product innovations. These innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyzer, the Stratus OCT™ and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery. The product portfolio in ophthalmic surgery is rounded off by intraocular lenses and consumables.

In the field of **neuro and ENT surgery**, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualisation solutions for a very broad range of applications, such as tumor and vascular surgery in the head region and/or spinal surgery. The most recent example of our innovative performance in the area of microsurgery is the OPMI Pentero® visualisation system, which allows efficient and ergonomic patient treatment. Carl Zeiss Meditec will systematically expand its product range in this area and become a solution provider in neuro and ENT surgery as well.

Carl Zeiss Meditec's medical technology portfolio is rounded off by visualisation systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery.

An aging global population, rising expectations of doctors and patients, together with innovative treatment methods in medical technology are expected to promote market growth in the long term. Carl Zeiss Meditec holds an optimum position for future developments in the health sector. The company focuses its solution portfolio on the three medical challenges with a significant social and economic impact: loss of mobility, vision and cognitive abilities. The goal is to deliver technologies and application-oriented solutions that allow doctors to improve the quality of life of their patients and to further improve the efficiency of diagnosis and treatment.

Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Meditec Surgical GmbH and Carl Zeiss Meditec Vertriebsgesellschaft mbH), the USA (Carl Zeiss Meditec, Inc., Dublin California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Ioltech SAS, La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).

**Press Release**

16 October 2007

Page 4 of 4



CARL ZEISS MEDITEC

Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry.

**Contact**

Jens Brajer/ Director Investor Relations  
Goeschwitzer Straße 51-52  
07745 Jena, Germany

Telefon: +49 (0) 36 41 - 2 20 - 1 05  
Telefax: +49 (0) 36 41 - 2 20 - 1 17

E-Mail: [investors@meditec.zeiss.com](mailto:investors@meditec.zeiss.com)  
Web: <http://www.meditec.zeiss.com>

**Press Release**

*END*